Yesterday we were the target of a small short seller that apparently makes its living publishing inaccurate content designed to mislead investors. We do not intend to respond through the media to a report that is riddled with inaccuracies, conjecture, and ill-informed
Tempus
1,397 posts
- We are excited to share that we have received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for our Tempus ECG-Low EF software, which uses AI to identify patients who may have a low left ventricular ejection fraction (LVEF). This is our second FDA approved
- Today, we shared our Q1 2025 results, highlights include: - Revenue increased 75.4% year-over-year to $255.7 million in the first quarter of 2025 - Quarterly gross profit increased 99.8% year-over-year, reaching $155.2 million with continued gross margin improvement in both
- We are thrilled to announce that we have received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for our updated Tempus Pixel, an AI-powered cardiac imaging platform. This update allows the generation of T1 and T2 inline maps, further enhancing the device’s
- We’re excited to announce our acquisition of @paige_ai, an AI company specializing in digital pathology. This acquisition allows us to grow our dataset, expand our experienced technical team, and establish a strong footprint in digital pathology with an industry leading
- We’re excited to announce the national launch of olivia, our AI-enabled personal health concierge app designed to empower patients by bringing their health-related data into one central location and leveraging advanced AI to provide actionable insights. The app enables patients
- We’re excited to share that we have received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for our Tempus xR IVD device. xR IVD will be offered as a life sciences tool to support drug development programs. The Tempus xR IVD assay is a qualitative next
- Today, we announced that we're building the largest foundation model that's ever been built in oncology, in collaboration with @AstraZeneca and @pathos. This project is the culmination of years of work. A foundation model like this has the potential to unlock a myriad of
- We’re excited to share an expansion of our longstanding collaboration with @NorthwesternMed to fully integrate David, our #gen-AI clinical co-pilot, within Northwestern’s #EHR platform for its clinical care team. This integration marks a new chapter in the our shared commitment
- Today, Tempus marks a decade of advancing data-driven precision medicine. We started with a mission to bring the power of artificial intelligence to healthcare, and today, we continue to build solutions that help physicians and researchers improve patient outcomes. Thank you to
00:00 - Today we shared our fourth quarter and full year 2024 results, including: - Revenue growth accelerated to 35.8% year-over-year in the fourth quarter of 2024 - Gross profit growth accelerated to 49.7% in the fourth quarter of 2024, led by Data and Services - Ended the year with
- We're excited to share the expansion of Tempus One—our generative AI clinical assistant—with direct integration into EHR systems. The AI-enabled clinical assistant is available to query patient data across the EHR as well as build custom agents to maximize workflow. Learn more
- A leading global pharmaceutical company leveraged Tempus Next to identify patients who may not be receiving guideline-based HER2 testing and gather insights on how to close that care gap. The Tempus Next HER2 program was able to identify 550 patients as potentially HER2+ and











